"Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials."
"In one of the largest real-world studies so far to examine long-term outcomes after discontinuing GLP-1 therapies, researchers found that a significant number of patients were able to maintain stable weight over a year."
A new analysis from Cleveland Clinic involving nearly 8,000 patients indicates that discontinuing GLP-1 medications like semaglutide and tirzepatide does not usually result in major weight regain. Many patients either restart their treatment or switch to alternative weight management options, helping them maintain stable weight. This study contrasts with earlier clinical trials that showed significant weight regain after stopping these medications. The findings suggest that real-world outcomes may differ due to patients' flexibility in adjusting their treatment plans.
Read at ScienceDaily
Unable to calculate read time
Collection
[
|
...
]